These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells. Choi YJ; Lee HW; Lee YS; Shim da M; Seo SW Tumour Biol; 2016 Apr; 37(4):4351-8. PubMed ID: 26499779 [TBL] [Abstract][Full Text] [Related]
45. P53 is required for Doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells. Sun Y; Xia P; Zhang H; Liu B; Shi Y Am J Cancer Res; 2016; 6(1):114-25. PubMed ID: 27073729 [TBL] [Abstract][Full Text] [Related]
46. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Itokazu M; Kumazawa S; Wada E; Wenyi Y Cancer Lett; 1996 Oct; 107(1):11-8. PubMed ID: 8913261 [TBL] [Abstract][Full Text] [Related]
47. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Dass CR; Khachigian LM; Choong PF Mol Cancer Ther; 2008 Jul; 7(7):1909-12. PubMed ID: 18645001 [TBL] [Abstract][Full Text] [Related]
48. Intranuclear Nanoribbons for Selective Killing of Osteosarcoma Cells. Liu S; Zhang Q; He H; Yi M; Tan W; Guo J; Xu B Angew Chem Int Ed Engl; 2022 Nov; 61(44):e202210568. PubMed ID: 36102872 [TBL] [Abstract][Full Text] [Related]
49. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777 [TBL] [Abstract][Full Text] [Related]
50. Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Bien S; Rimmbach C; Neumann H; Niessen J; Reimer E; Ritter CA; Rosskopf D; Cinatl J; Michaelis M; Schroeder HW; Kroemer HK Biochem Pharmacol; 2010 Nov; 80(10):1466-77. PubMed ID: 20709028 [TBL] [Abstract][Full Text] [Related]
51. Depletion of Neuroguidin/CANu1 sensitizes human osteosarcoma U2OS cells to doxorubicin. Park JH; Sihn CR; Lee YS; Lee SJ; Kim SH BMB Rep; 2011 Jan; 44(1):46-51. PubMed ID: 21266106 [TBL] [Abstract][Full Text] [Related]
52. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530 [TBL] [Abstract][Full Text] [Related]
53. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036 [TBL] [Abstract][Full Text] [Related]
54. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Zhao Y; Zhang CL; Zeng BF; Wu XS; Gao TT; Oda Y Biochem Biophys Res Commun; 2009 Dec; 390(3):642-7. PubMed ID: 19818735 [TBL] [Abstract][Full Text] [Related]
55. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083 [TBL] [Abstract][Full Text] [Related]